This Medudy course is a video tutorial for physicians on the topic of "Combination therapy with ivonescimab in EGFR-positive NSCLC". The format used here is a so-called "Journal Club Summary", in which we summarize the latest and most clinically relevant studies for you.
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line treatment for patients with non-small cell lung cancer (NSCLC) and EGFR mutation.
However, if the disease progresses under EGFR-TKIs, treatment options are limited.
Today's study is the first Phase 3 study to evaluate the efficacy of ivonescimab in combination with chemotherapy compared to chemotherapy alone in EGFR-positive NSCLC with EGFR-TKI resistance.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this course you will know
- the clinical background and relevance of the research question under investigation
- the study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
